SCHEMBL6093747

SCHEMBL6093747

CCOCCC(OCC)OC(=O)OC(C(C)C)n1nc(C(=O)OCC)c(C(=O)c2ccc(OC)c(OC(C)C)c2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.39
ALDH1A1 P00352 3/20 0.39
MAPK1 P28482 2/20 0.39
PDE4B Q07343 1/20 0.36
ABCB1 P08183 1/20 0.33
LMNA P02545 2/20 0.32
HSD17B2 P37059 1/20 0.32
TUBB4A P04350 1/20 0.32
TUBB P07437 1/20 0.32
TUBA3C P0DPH7 1/20 0.32
TUBA1B P68363 1/20 0.32
TUBA4A P68366 1/20 0.32
TUBB4B P68371 1/20 0.32
TUBB3 Q13509 1/20 0.32
TUBB2A Q13885 1/20 0.32
TUBB8 Q3ZCM7 1/20 0.32
TUBA3E Q6PEY2 1/20 0.32
TUBA1A Q71U36 1/20 0.32
TUBA1C Q9BQE3 1/20 0.32
TUBB6 Q9BUF5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6092816 0.95 MAPT (0.38) MAPTALDH1A1MAPK1ABCB1LMNA
SCHEMBL5515783 0.88 MAPT (0.46) MAPTALDH1A1MAPK1PDE4BABCB1
SCHEMBL6095019 0.87 ALDH1A1 (0.33) MAPTALDH1A1MAPK1
SCHEMBL5513897 0.86 MAPT (0.42) MAPTALDH1A1MAPK1PDE4BABCB1
SCHEMBL6095516 0.85 POLB (0.35) MAPTALDH1A1MAPK1LMNAPOLB
SCHEMBL5516128 0.83 MAPT (0.43) MAPTALDH1A1MAPK1ABCB1LMNA
SCHEMBL6093093 0.83 KDM4E (0.31) MAPTKDM4E
SCHEMBL6095822 0.80 POLB (0.37) MAPTALDH1A1LMNAPOLBMEN1
SCHEMBL5518587 0.74 MAPT (0.38) MAPTALDH1A1MAPK1PDE4BLMNA
SCHEMBL5517835 0.73 MAPT (0.35) MAPTALDH1A1MAPK1PDE4BPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7022860-B2 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-04 US disclosed
US-20020137739-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA PHARMA CO., LTD. (JP) 2002-09-26 US disclosed
US-6372735-B1 ANTIHISTAMINES MEIJI SEIKA KAISHA, LTD. (JP) 2002-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137739-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents HRH4, CYP3A4, TPH1 MAPT 3223/4885ALDH1A1 691/4885MAPK1 4220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.